Imagine learning surgery without touching a real patient. No risk. No panic. No second chances needed.
That’s exactly the world Maverick Simulation Solutions is building.
A Delhi-based medtech company is quietly turning medical training into a high-tech, simulation-driven experience — and the numbers suggest it’s working.
Maverick Simulation Solutions operates in a niche but fast-growing segment — medical simulation.
Instead of learning on real patients, doctors and nurses train using hyper-realistic simulators.
We’re talking about:
-
Full-body patient simulators
-
Surgical training systems
-
Injection arms and airway trainers
-
Virtual anatomy and dissection tables
And these aren’t cheap toys.
Some high-fidelity systems cost up to ₹5 crore.
Here’s where Maverick stands out.
It doesn’t just sell equipment. It builds entire simulation labs.
Think of it like this:
-
Hardware (simulators)
-
Software (AR/VR, digital anatomy)
-
Infrastructure (lab setup)
All bundled into a turnkey solution.
Customers?
-
Medical colleges
-
Hospitals
-
Nursing institutes
Revenue isn’t just one-time sales — it’s large, high-ticket institutional deals.
Maverick combines:
-
In-house R&D
-
Global technology collaborations
-
AR/VR-based training
This puts it in a sweet spot — where healthcare meets immersive technology.
And as medical education modernizes, demand for simulation-based learning is rising globally.
Now comes the interesting part.
-
FY24: ₹14.2 crore
-
FY25: ₹136.3 crore
That’s nearly a 10x jump in just one year.
-
EBITDA: ₹1.12 crore → ₹61.34 crore
-
PAT: ₹0.94 crore → ₹47.8 crore
Margins expanded massively:
-
EBITDA Margin: 7.89% → 45%
-
Net Profit Margin: 6.62% → 35.07%
This isn’t just growth. It’s explosive operating leverage.
A few possibilities explain this sharp jump:
Simulation labs are high-ticket projects. Even a few big deals can significantly boost revenue.
FY24 had negative inventory adjustments. FY25 reversed that trend — improving margins.
Once R&D is done, incremental sales come at much higher margins.
-
Market Cap: ₹1007 crore
-
P/E Ratio: 21.07
-
ROE: 49.32%
-
Debt/Equity: 0.24
-
Book Value: ₹217.57
At first glance:
-
High profitability
-
Strong return ratios
-
Low leverage
But the key question remains — is this sustainable?
The business looks promising, but investors need to dig deeper.
Key things to watch:
Are revenues backed by long-term contracts or one-off deals?
Do institutions come back for upgrades and expansions?
Can Maverick scale beyond India?
Will AR/VR integration create a long-term moat?
Here’s where things get interesting.
On paper, Maverick looks like a cash machine.
But the balance sheet and cash flow statement tell a very different story.
-
Reserves jumped from ₹21 Cr → ₹92 Cr
-
Borrowings increased from ₹7.8 Cr → ₹23 Cr
This combination gave the company the financial muscle to scale aggressively.
-
Higher reserves = stronger net worth (internal funding)
-
Higher borrowings = external fuel for working capital
Together, they enabled Maverick to execute its ₹136 Cr revenue jump.
Despite ₹136 Cr revenue, cash at the end of FY25 is just ~₹7 Cr.
Why?
-
Trade Receivables: ₹5 Cr → ₹105.4 Cr
That means most of the revenue is not cash — it’s credit.
Maverick has essentially:
-
Sold products worth ₹136 Cr
-
But collected only a small portion in cash
The rest is stuck as “money to be received.”
-
Cash Flow from Operations: Negative (~₹-21 Cr)
-
Working Capital Change: ₹-77 Cr
Even after massive profits, the business is burning cash operationally.
Maverick is funding customer purchases.
Instead of customers paying upfront, the company is:
-
Delivering high-value simulation systems
-
Allowing delayed payments
This creates growth — but at the cost of liquidity.
Maverick Simulation Solutions sits at the intersection of:
-
Healthcare
-
Education
-
Deep tech
And its FY25 performance shows what happens when a niche business hits scale.
But here’s the catch —
When growth is this sharp, consistency becomes the real test.
Because in the world of simulations,
predictability matters more than performance.
-
40+ simulators in portfolio
-
End-to-end simulation lab solutions
-
High-ticket deals (up to ₹5 crore per system)
-
Strong FY25 financial breakout
If Maverick can sustain this momentum, it won’t just train doctors.
It could redefine how medicine is learned altogether.